Question

In: Accounting

Amy Dyken, controller at Waterway Pharmaceutical Industries, a public company, is currently preparing the calculation for...

Amy Dyken, controller at Waterway Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Waterway’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020.

Waterway Pharmaceutical Industries
Selected Balance Sheet Information
June 30, 2020
Long-term debt      
Notes payable, 10% $990,000
8% convertible bonds payable       5,030,000
10% bonds payable 5,880,000
Total long-term debt $11,900,000
       
Shareholders’ equity      
Preferred stock, 5% cumulative, $50 par value, 107,000 shares authorized, 26,750 shares issued and outstanding $1,337,500
Common stock, $1 par, 9,800,000 shares authorized, 980,000 shares issued and outstanding 980,000
Additional paid-in capital 3,940,000
Retained earnings 6,110,000
Total shareholders’ equity $12,367,500

The following transactions have also occurred at Waterway.

1.       Options were granted on July 1, 2019, to purchase 190,000 shares at $15 per share. Although no options were exercised during fiscal year 2020, the average price per common share during fiscal year 2020 was $20 per share.
2.       Each bond was issued at face value. The 8% convertible bonds will convert into common stock at 50 shares per $1,000 bond. The bonds are exercisable after 5 years and were issued in fiscal year 2019.
3.       The preferred stock was issued in 2019.
4.       There are no preferred dividends in arrears; however, preferred dividends were not declared in fiscal year 2020.
5.       The 980,000 shares of common stock were outstanding for the entire 2020 fiscal year.
6.       Net income for fiscal year 2020 was $1,490,000, and the average income tax rate is 20%.

For the fiscal year ended June 30, 2020, calculate the following for Waterway Pharmaceutical Industries. (Round answers to 2 decimal places, e.g. $2.45.)

(a) Basic earnings per share.

Basic earnings per share      
$ (?)

(b) Diluted earnings per share.

Diluted earnings per share      
$ (?)

Solutions

Expert Solution

Please find below table useful to compute desired results: -

End results would be as follows: -


Related Solutions

Amy Dyken, controller at Sheridan Pharmaceutical Industries, a public company, is currently preparing the calculation for...
Amy Dyken, controller at Sheridan Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Sheridan’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Sheridan Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% $1,010,000 9% convertible bonds payable 5,090,000 10% bonds payable 6,060,000 Total long-term debt $12,160,000 Shareholders’ equity Preferred stock, 6% cumulative, $50 par...
Amy Dyken, controller at Marigold Pharmaceutical Industries, a public company, is currently preparing the calculation for...
Amy Dyken, controller at Marigold Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Marigold’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Marigold Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt    Notes payable, 11% $980,000    8% convertible bonds payable 5,030,000    11% bonds payable 6,100,000      Total long-term debt $12,110,000 Shareholders’ equity    Preferred stock, 6% cumulative, $50 par...
Question 4 Amy Dyken, controller at Marigold Pharmaceutical Industries, a public company, is currently preparing the...
Question 4 Amy Dyken, controller at Marigold Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Marigold’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Marigold Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% $1,020,000 8% convertible bonds payable 5,080,000 10% bonds payable 6,110,000 Total long-term debt $12,210,000 Shareholders’ equity Preferred stock, 6% cumulative,...
Problem 16-5 Amy Dyken, controller at Kingbird Pharmaceutical Industries, a public company, is currently preparing the...
Problem 16-5 Amy Dyken, controller at Kingbird Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Kingbird’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2017. KINGBIRD PHARMACEUTICAL INDUSTRIES SELECTED BALANCE SHEET INFORMATION JUNE 30, 2017 Long-term debt Notes payable, 9% $1,000,000 8% convertible bonds payable 4,910,000 9% bonds payable 6,080,000 Total long-term debt $11,990,000 Shareholders’ equity Preferred stock, 7% cumulative,...
Problem 16-5 Amy Dyken, controller at Ivanhoe Pharmaceutical Industries, a public company, is currently preparing the...
Problem 16-5 Amy Dyken, controller at Ivanhoe Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Ivanhoe’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2017. IVANHOE PHARMACEUTICAL INDUSTRIES SELECTED BALANCE SHEET INFORMATION JUNE 30, 2017 Long-term debt    Notes payable, 11% $1,010,000    8% convertible bonds payable 5,050,000    11% bonds payable 5,950,000      Total long-term debt $12,010,000 Shareholders’ equity    Preferred stock, 6% cumulative,...
Problem 16-5 Amy Dyken, controller at Buffalo Pharmaceutical Industries, a public company, is currently preparing the...
Problem 16-5 Amy Dyken, controller at Buffalo Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Buffalo’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2017. BUFFALO PHARMACEUTICAL INDUSTRIES SELECTED BALANCE SHEET INFORMATION JUNE 30, 2017 Long-term debt Notes payable, 10% $1,000,000 8% convertible bonds payable 5,080,000 10% bonds payable 5,940,000 Total long-term debt $12,020,000 Shareholders’ equity Preferred stock, 6% cumulative,...
Eye Trendy Corporation is a distributor of frames for sunglasses. The company’s controller is currently preparing...
Eye Trendy Corporation is a distributor of frames for sunglasses. The company’s controller is currently preparing a budget for the third quarter of the year. The following information is from company’s financial records: Projected Sales July 3,120 units August 2,000 units September 2,640 units October 3,000 units • Selling price is RM25 per unit • Collections from customers are normally 70 per cent in the month of sale, 20 per cent in the month following sale, and 9 per cent...
Waterway Company is a manufacturer of smart phones. Its controller resigned in October 2020. An inexperienced...
Waterway Company is a manufacturer of smart phones. Its controller resigned in October 2020. An inexperienced assistant accountant has prepared the following income statement for the month of October 2020. WATERWAY COMPANY Income Statement For the Month Ended October 31, 2020 Sales revenue $794,700 Less: Operating expenses Raw materials purchases $263,200 Direct labor cost 188,000 Advertising expense 92,400 Selling and administrative salaries 77,500 Rent on factory facilities 62,800 Depreciation on sales equipment 45,100 Depreciation on factory equipment 32,600 Indirect labor...
Oman Pharmaceutical Industries Co. (OPP) is one of the fastest growing pharmaceutical company in GCC. It...
Oman Pharmaceutical Industries Co. (OPP) is one of the fastest growing pharmaceutical company in GCC. It manufactures four joint products Azithromycin, Clarithromycin, Levofloxacin and Moxifloxacin from a chemical process. After further processing, the company sells Azithromycin, Clarithromycin, Levofloxacin and Moxifloxacin at a price of RO 20, RO 24, RO 16 and RO 12 and estimates a profit of 17.5%, 12.5%, 12.5% and 15% respectively. The costs incurred till the split- off point are RO 39,000. The output achieved at the...
Lowell Company makes and sells artistic frames for pictures. The controller is responsible for preparing the...
Lowell Company makes and sells artistic frames for pictures. The controller is responsible for preparing the master budget and has accumulated the following information for 2020. January February March April May Estimated unit sales 10,300 11,600 9,000 8,300 8,000 Sales price per unit $50.30 $48.70 $48.70 $48.70 $48.70 Direct labor hours per unit 2.3 2.3 1.6 1.6 1.6 Wage per direct labor hour $8 $8 $8 $9 $9 Lowell has a labor contract that calls for a wage increase to...
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT